

Summary Sustainability Requirements

Summary – Chemicals & Pharma

Why does ABN AMRO have a sustainability policy for Chemicals & Pharma?

ABN AMRO strives to create long-term value for its stakeholders, to respect human rights, safeguard the environment and curb climate change. The bank recognizes that in its role as a financial service provider it may be exposed to social, climate, environmental and ethical risks through the activities of clients. To manage these sustainability risks, ABN AMRO operates a Sustainability Risk Policy Framework in line with the banks moderate risk profile.

More specifically, ABN AMRO has formulated sustainability requirements for clients in the chemicals & pharma industry. ABN AMRO acknowledges that the chemicals & pharma sector poses sustainability risks, such as:

- Extremely Hazardous Substances; The chemicals & pharma industry may be exposed to the use of hazardous and toxic substances that are subject to international phase outs or that do not comply with regulations such as REACH and the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal.
- Pollution; The chemicals & pharma sector may cause pollution of air, water and/or soil due to irresponsible handling of substances;
- Health & Safety; Employees may face health and safety issues due to improper handling of substances and/or inappropriate safety measures;
- Integrity of local communities; Chemicals and pharma activities may potentially have harmful impact on the living environment of local communities due to pollution of the local environment and/or displacement;;
- Animal Welfare; some new chemical and pharmaceutical products are first tested on animals for example for commercial purposes or involve endangered species.

What is the scope?

The requirements apply to lending clients of ABN AMRO and all its subsidiaries, branches and representative offices and legal entities that are under its control, in the following subsectors:

- Chemical production, including the manufacturing of base, intermediate and specialty chemicals and gasses.
- Chemical and pharmaceutical trade
- Pharmaceuticals, including the production of drugs and pharmaceutical (medial) supplies

Due-diligence standards

For all three subsectors, ABN AMRO applies a set of minimum requirements and benchmark criteria. ABN AMRO will only finance clients who comply with all applicable minimum requirements, or have an improvement plan in place to do so within a limited timeframe. The benchmark criteria, which are aligned with international best practices, are used to compare the client's performance with their industry peers on an ongoing basis. An overview of the applicable minimum requirements and benchmark criteria for the three subsectors is included in the appendix below.

ABN AMRO has an inclusive approach. This means that the bank will engage with clients who do not yet meet the bank's minimum requirements, but who are willing and able to do so within a limited timeframe. The exception to this inclusive approach concerns activities on ABN AMRO's Exclusion List; as these activities are simply too risky from a sustainability perspective.

How does ABN AMRO put its standards into practice?

In accordance with its Sustainability Risk Standard for Lending and Project Finance, ABN AMRO puts its sustainability standards into practice through a sustainability risk management process. This covers the following steps; risk determination, risk assessment, approval of the transaction and monitoring and reporting. ABN AMRO reviews (prospective) clients at various moments to determine their compliance with the bank's Policy:

- During the client onboarding and review process;
- During the credit approval and review process for clients with an exposure over 1 million Euro.

Appendices:

Appendix 1: sustainability standards for Chemical Producers

Appendix 2: sustainability standards for Chemical Traders

Appendix 3: sustainability standards for Pharmaceutical Companies

Appendix 1 - Requirements Chemicals Producers

		Minimum requirements	Benchmarks
Со	mpliance		
1.	Clients comply with all national and international laws and regulations applicable to them (e.g. REACH, Rotterdam Convention, Stockholm Convention, Basel convention), have obtained and maintain all requisite permits and licences, and ensure continuous compliance with them.	X	
2.	Clients have an anti-corruption and anti-bribery policy in place.	V	
Ha	zardous substances	X	
3.	Clients using and/or producing hazardous substances and/or hazardous waste explain the appropriate steps taken to prevent harm to human health and the environment. They do so in accordance with the precautionary principle.	X	
4.	Clients have a system in place that ensures the appropriate identification, labelling and documentation of hazardous substances as they appear during any stage of the client's operations.	X	
5.	Clients have a strategy to look proactively for more sustainable alternatives to the substances they use or develop.		X
Du	e diligence & policies		
6.	Clients have identified their key human rights impacts and risks and have a policy in place specifying how human rights risks associated with their processes and products are addressed, in accordance with the UN Guiding Principles.	X	
7.	Clients have identified their key environmental risks and have an environmental policy in place specifying how it addresses environmental risks associated with their processes and products.	X	
8.	Clients have identified their key health and safety risks and have a health and safety policy in place specifying how these risks are addressed.	X	
9.	Clients have an emergency response plan in place that includes communication and cooperation with local communities and authorities in case of emergencies.	X	
10.	Clients operate in accordance with the principles of Responsible Care.	Х	
Sta	keholder engagement		
11.	Clients have (a strategy to) effectively disclose and communicate relevant environmental, human rights and health & safety risks and impacts of their operations and products to (potentially) affected stakeholders.	X	
12.	Clients have in place effective operational-level grievance mechanisms for stakeholders who may be adversely impacted.	X	
13.	Clients report on the (aggregated) number and content of grievances received and addressed.		Х
Tra	ck record and reporting		
14.	Clients have set SMART targets on at least the following key performance indicators:	X	
	a. fatalities and (lost time on) injuries,		
	 emissions of greenhouse gases and other pollutants (e.g. NOx, SO₂), 		
	c. use of resources (e.g. energy, water).		
15.	Clients report on their environmental, human rights and health & safety performance. This includes the disclosure of incidents and results on key performance indicators (requirement 14).	X ¹	
16.	Bank clients have a good track record, in terms of: a. incident rates (e.g. spills, fires, injuries, fatalities, fraud/corruption cases, human rights violations) are low or show consistent decline	X	

 $^{\rm 1}\,{\rm Minimum}$ requirement for large globally operating listed companies.

		over time,		
	b.	the client has a demonstrated capacity in comprehensive and transparent response management and to adequately address issues,		
	C.	inspection authorities have not reported structural shortcomings in the client's management of environmental and social risks,		
	d.	there is no or limited bad press on the sustainability performance of the client and/or the client has responded adequately to it.		
G٥١	/ernance			
17.	safety p	sponsibility for the client's human rights, environmental and health & olicies and practices lies with a dedicated member of senior ement or board.	X	
18.	Health & with inte objective monitor	are expected to have a corporate Environmental and Social and a & Safety Management System (ESMS) in place. The ESMS is in line ernational standards such as ISO:14001 and OHSAS:18001, has clear es and targets and includes documented procedures to mitigate, and measure, on a regular basis, the environmental, human rights alth & safety impacts and risks of the business operations.	X	
19.	guarant	have operational guidelines in place for each individual site to ee that corporate commitments and policies are supported and d with at individual sites.	X	
20.		nel are trained on relevant environmental, human rights, health and sks and compliance with the company's policies to mitigate these	X	
Sup	ply cha	in due diligence/transparency		
21.		apply environmental, human rights and health & safety criteria in the nof suppliers, service providers and contractors.	X	
22.	which a	have an obligatory supplier code of conduct or equivalent in place ddresses the key environmental, social and health and safety risks in oply chain.		X
23.		monitor the environmental, human rights and health & safety ance of their suppliers.		Х
24.		undertake to identify the environmental, social/human rights and a safety risks in their upstream and downstream supply chain.		X
25.	product	producing intermediate or specialty chemicals strive to minimize their s' environmental impact throughout all stages of the products' life roduct stewardship).		X
Oth	er			
26.	Clients	participate in relevant initiatives for sustainability and/or circular y.		X
27.		making use of animal testing have an animal welfare policy based on ciples of the 3R-strategy of replace, reduce, refine.	X	

Appendix 2 - Requirements Chemicals Traders

		Minimum requirement	Benchmarks
Co	mpliance & policies		
1.	Clients comply with all national and international laws and regulations applicable to them (e.g. REACH, Rotterdam Convention, Stockholm Convention, Basel convention), have obtained and maintain all requisite permits and licences, and ensure continuous compliance with them.	X	
2.	Clients have an anti-corruption and anti-bribery policy in place.	X	
3.	Clients have identified their key environmental, human rights and health & safety risks, and have a code of conduct or policy in place specifying how it addresses these risks.	X	
4.	Clients operate in accordance with the principles of Responsible Care.		X

		have in place effective operational-level grievance mechanisms for lders who may be adversely impacted.		X
		substances		
a	ppropr	trading hazardous substances and/or hazardous waste explain the iate steps taken to prevent harm to human health and the ment. They do so in accordance with the precautionary principle.	X	
la a	abelling ny stag	have a system in place that ensures the appropriate identification, g and documentation of hazardous substances as they appear during ge of the client's operations.	X	
Track	recor	d and reporting		
	lients erform	report on their environmental, human rights and health & safety ance.		X
9. E	Bank clients have a good track record, in terms of:			
	a.	incident rates (e.g. spills, fires, fraud/corruption cases, human rights violations) are low or show consistent decline over time,	X	
	b.	the company has a demonstrated capacity in comprehensive and transparent response management,		
	C.	inspection authorities have not reported structural significant shortcomings in the company's management of environmental and social risks,		
	d.	there is no or limited bad press on the sustainability performance of the client and/or it has responded adequately to it.		
Gove	rnanc	B		
(E	ESMS)	have a corporate Environmental and Social Management System in place. The ESMS is in line with international standards such as 001 and OHSAS:18001.		Х
Suppl	ly cha	in due diligence/transparency		
		apply environmental, human rights and health & safety criteria in the nof suppliers, service providers and contractors.		X
w th	hich a neir su	have an obligatory supplier code of conduct or equivalent in place ddresses the key environmental, social and health and safety risks in pply chain.		X
Other	•			
	lients conom	participate in relevant initiatives for sustainability and/or circular ny.		Х

Appendix 3 - Requirements Pharmaceutical Companies

		Minimum requirements	Benchmarks
Со	mpliance		
1.	Clients comply with all national and international laws and regulations applicable to them, have obtained and maintain all requisite permits and licences, and ensure continuous compliance with them.	X	
Du	e diligence & policies		
2.	Clients have a code of conduct in place, which addresses at least corruption, unethical marketing and anti-competitive behaviour that may restrict access to medicine.	X	
3.	Clients have identified their key human rights impacts and risks, in particular regarding the right to health, and have a policy in place specifying how it addresses these impacts and risks associated with their processes and products, in accordance with the UN Guiding Principles on Business and Human Rights.	X	
4.	Clients proactively undertake to ensure the accessibility of their pharmaceutical products.		X
5.	Clients have identified their key environmental and health & safety risks and have a policy in place specifying how it addresses these risks associated with their processes and products.	X	

6.	Clients producing antibiotics are aware of the specific risks related to antibiotics resistance and take appropriate measures, throughout the entire life cycle of the product.	X	
7.	Clients making use of animal testing have an animal welfare policy based on the principles of the 3R-strategy of replace, reduce, refine.	X	
Sta	keholder engagement		
8.	Clients have in place effective operational-level grievance mechanisms for stakeholders who may be adversely impacted.	X	
9.	Clients report on the aggregated number and content of grievances received and addressed.		X
Tra	nsparency and track record		
10.	Clients have set SMART targets on at least the following key performance indicators:		
	a. emissions of greenhouse gases and other pollutants,b. use of resources (e.g. energy, water),	Х	
	c. waste.		
11.	Clients report on their environmental, human rights and health & safety performance. This includes the disclosure of incidents and results on key performance indicators (requirement 9).	X ²	
12.	Bank clients have a good track record, in terms of:		
	incident rates (e.g. spills, fires, injuries, fatalities, fraud/corruption cases, human rights violations) are low or show consistent decline over time,		
	 inspection authorities have not reported structural significant shortcomings in the company's management, 	Χ	
	c. there is no or limited bad press on the sustainability performance of the client and/or it has responded adequately to it.		
Go	vernance		
13.	Final responsibility for the client's human rights, environmental and health & safety policies and practices lies with a dedicated member of senior management or board.	X	
	Clients have a corporate Environmental and Social and Health and Safety Management System (ESMS) in place, which ensures compliance with applicable legislation and company policies. The ESMS is in line with international standards such as ISO:14001 or OHSAS:18001.	X	
Su	oply chain due diligence		•
15.	Clients apply environmental, human rights and health & safety criteria in the selection of suppliers, service providers and contractors.	X	
16.	Clients have an obligatory supplier code of conduct or equivalent in place which addresses the key environmental, social and health and safety risks in their supply chain.		Х
	Clients take responsibility for the correct use and disposal of their pharmaceutical products.	X	
Oth	er		
18.	Clients participate in relevant initiatives for transparency and/or sustainability (e.g. Access to Medicine index).		X

_

 $^{^{\}rm 2}$ Minimum requirement for large globally operating listed companies.